Bactericidal Effect of Synthetic Phenylalkylamides Inspired by Gibbilimbol B Against Neisseria gonorrhoeae
- PMID: 40509293
- PMCID: PMC12156809
- DOI: 10.3390/molecules30112406
Bactericidal Effect of Synthetic Phenylalkylamides Inspired by Gibbilimbol B Against Neisseria gonorrhoeae
Abstract
Increasing multidrug resistance in Neisseria gonorrhoeae poses a serious and escalating public health crisis. The World Health Organization has classified N. gonorrhoeae as a high-priority pathogen for developing new antimicrobials. Natural products provide a promising avenue for antimicrobial discovery, serving as direct therapeutic agents or prototypes for novel drug development. Among these, gibbilimbol B, a compound isolated from Piper malacophyllum, is particularly attractive due to its biological potential and simple structure. In this study, eight synthetic phenylalkylamides (1-8) inspired by gibbilimbol B were synthesized and evaluated for their antibacterial activity against N. gonorrhoeae. The in vitro bacterial assays revealed that these compounds exhibit notable antibacterial activity, including against resistant strains selected from the CDC/FDA antimicrobial panel (strains AR-173, AR-174, AR-187, and AR-200). All synthesized compounds demonstrated superior efficacy in killing N. gonorrhoeae compared to gibbilimbol B. Notably, compound 8 [(E)-4-chloro-N-(oct-4-en-1-yl)benzamide] showed an MBC50 of 6.25 µM, representing a four-fold improvement in bactericidal activity over the natural compound. This study represents the first exploration of gibbilimbol analogs for antibacterial applications, highlighting the novelty of the work and paving the way for the development of new antibacterial agents.
Keywords: Neisseria gonorrhoeae; analogs; bactericidal; gibbilimbol B; natural products.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures




Similar articles
-
Potent and rapid antigonococcal activity of the venom peptide BmKn2 and its derivatives against different Maldi biotype of multidrug-resistant Neisseria gonorrhoeae.Peptides. 2014 Mar;53:315-20. doi: 10.1016/j.peptides.2013.10.020. Epub 2013 Oct 31. Peptides. 2014. PMID: 24184420
-
Cyclization increases bactericidal activity of arginine-rich cationic cell-penetrating peptide for Neisseria gonorrhoeae.Microbiol Spectr. 2024 Sep 3;12(9):e0099724. doi: 10.1128/spectrum.00997-24. Epub 2024 Aug 6. Microbiol Spectr. 2024. PMID: 39105587 Free PMC article.
-
Antimicrobial Activity of Auranofin, Cannabidivarin, and Tolfenamic Acid against Multidrug-Resistant Neisseria gonorrhoeae.Microbiol Spectr. 2022 Dec 21;10(6):e0395222. doi: 10.1128/spectrum.03952-22. Epub 2022 Nov 9. Microbiol Spectr. 2022. PMID: 36350125 Free PMC article.
-
Neisseria gonorrhoeae and fosfomycin: Past, present and future.Int J Antimicrob Agents. 2015 Sep;46(3):290-6. doi: 10.1016/j.ijantimicag.2015.05.007. Epub 2015 Jun 19. Int J Antimicrob Agents. 2015. PMID: 26145201 Review.
-
Expanding U.S. Laboratory Capacity for Neisseria gonorrhoeae Antimicrobial Susceptibility Testing and Whole-Genome Sequencing through the CDC's Antibiotic Resistance Laboratory Network.J Clin Microbiol. 2020 Mar 25;58(4):e01461-19. doi: 10.1128/JCM.01461-19. Print 2020 Mar 25. J Clin Microbiol. 2020. PMID: 32024723 Free PMC article. Review.
References
-
- WHO . Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report 2022. World Health Organization; Geneva, Switzerland: 2022.
-
- World Health Organization . WHO Bacterial Priority Pathogens List, 2024: Bacterial Pathogens of Public Health Importance to Guide Research, Development and Strategies to Prevent and Control Antimicrobial Resistance. WHO; Geneva, Switzerland: 2024.
-
- World Health Organization WHO Publishes List of Bacteria for Which New Antibiotics Are Urgently Needed. [(accessed on 19 February 2023)]. Available online: https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-....
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials